← Back to Search

Tenalisib for Blood Cancers

Phase 1 & 2

Waitlist Available

Research Sponsored by Rhizen Pharmaceuticals SA

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is for a new drug that has shown some promise in treating patients with cancer who have relapsed or are unresponsive to other treatments. The safety and efficacy of the drug will be further evaluated in this trial.

Eligible Conditions

Blood Cancers

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time to disease progression

Side effects data

From 2020 Phase 2 trial • 21 Patients • NCT04204057

29%

Anemia

24%

Neutropenia

19%

Alanine aminotransferase increased

19%

Aspartate aminotransferase increased

10%

Pneumonia

10%

Thrombocytopenia

10%

Diarrhea

10%

Blood alkaline phosphatase increased

100%

80%

60%

40%

20%

Study treatment Arm

Tenalisib

Trial Design

1Treatment groups

Experimental Treatment

Group I: TenalisibExperimental Treatment1 Intervention

Participants receive Tenalisib (RP6530) BID Orally

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tenalisib

2019

Completed Phase 2

~120

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rhizen Pharmaceuticals SALead Sponsor

16 Previous Clinical Trials

573 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any unfilled vacancies for this particular clinical trial?

"This trial is not enrolling patients at the moment, as seen by the date of the most recent edit to the posting. However, there are 2616 other trials for hematologic neoplasms and 2 trials for Tenalisib that are actively recruiting."

Answered by AI

Are there similar studies that have been conducted with Tenalisib?

"Tenalisib was first researched in 2018 at Medivest - Institute of Hematology and Transfusiology. So far, 3 trials have completed with 2 more recruiting patients as we speak. These ongoing studies are based in Denver, Colorado."

Answered by AI

Where can I find a list of all the places where this research is being conducted?

"The trial is based in the Division of Hematology at University of Colorado, Denver; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; The University of Texas MD Anderson Cancer Center, Houston as well as four other locations."

Answered by AI

Has this type of trial been done before?

"Tenalisib has been under investigation since 2018. The first Phase 1 & 2 clinical trials were completed in that year and sponsored by Rhizen Pharmaceuticals SA. After the initial study, which had a sample size of just 17 individuals, Tenalisib received approval for further testing. As of now, there are two ongoing studies involving Tenalisib being conducted in 4 metropolises and 3 countries."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Compassionate Use Study of Tenalisib (RP6530)

2018. "Compassionate Use Study of Tenalisib (RP6530)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03711604.